Bibliographie

Publié le 27/03/2009

Article réservé aux abonnés

1- The CURE Trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without-ST segment elevation. N Engl J Med 2001; 345 : 494-502.

2- Mehta SR, Yusuf S, Peters RJ et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.

3- Sabatine MS, Cannon CP, Gibson MC and CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinomytic therapy for myocardial infarction with ST-segement elevation. N Engl J Med... 2005.vol 252, N°12;p1179-1189

4- Clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Addition to clopidogrel to aspirin in 45 852 patients with acute myocardial infarction : randomised placebo-controlled trial.Lancet 2005 ; 366 :1607-21

5- Budaj A, Brieger D, Steg PG et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003; 146: 999-1006.

6- Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of cardiology. Eur Heart J 2004;25:166-81

7- DL. Bhatt, PG. Steg, EM. Ohman et al. au nom des chercheurs du registre REACH. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 ; 295:180-189.

8- Danchin N. , Thebaut J-F, Dievart F et al. Prévention secondaire après syndrome coronaire aigu sans sus-décalage de ST en fonction de l'utilisation de l'angioplastie coronaire : l'étude S-témoin. Annales de cardiologie et d'angéiologie. 2007, vol. 56, no1, pp. 30-35

9- Sabouret P., Asseman P ., Dallongeville J. et al. Influence of PCI on the edherence to discharge guideline – Recommended therapies in ACS patients : the CONNECT study. Auropean Society of Cardiology, August 30 – September 03, 2008, Munich.

10- Frans Van de Werf. Dual antiplatelet therapy in high-risk patients. European Heart Journal. Supplements (2007) 9 (Supplement D), D3–D9

11- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

12- Sacco RL, Diener HC, Yusuf S et al. PRoFESS Study Group. N Engl J Med. 2008 Sep 18;359(12):1238-51. Epub 2008 Aug 27.

13 - Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) ; a randomised, double-blind, placebo-controlled trial. Lancet 2004 ; 364 : 331-37.

14- Welten GM, Schouten O, Hoeks SE et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008 Apr 22;51(16):1588-96.

15- Belch J, MacCuish A, Campbell I et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 Oct 16;337:a1840. doi: 10.1136/bmj.a1840.

16- Hansson L, Zanchetti A, Camuthers SC et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hpertension Optimal Treatment randomized trial. Lancet 1998 ; 351 : 1755-62.

17- Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerosis events in patients with type 2 diabetes. A randomized controlled trial. JAMA 2008;300:2134-41

18- Bhatt DL, Fox KA, Hacke W et al. cCHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17.

19- Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction : a cohort study. Lancet 2009;373:309-17.

20- Mega LM, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and Response to Clopidogrel. New Engl J Med N Engl J Med. 2009 Jan 22;360(4):354-62

21- Simon T, Verstuyft C, Mary-Krause M et al for the FAST-MI Investigators. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New Engl J Med. 2009 Jan 22;360(4):363-75.